Development of Surgical Site Infection One Year After Thyroplasty With Arytenoid Adduction.

Delayed complications of arytenoid adduction and medialization laryngoplasty are rarely reported in the literature. Clinicians should be aware that performing an AA alongside an ML may seed oral cavity bacteria into the paralaryngeal space. This may result in delayed infection-especially in immunocompromised patients-necessitating implant removal and antibiotics.

Study to localize isometric points of anterior band of inferior glenohumeral ligament and to use long head of biceps as a graft: A finite element analysis and arthroscopic cadaveric demonstration.

Background: The inferior glenohumeral ligament (IGHL) comprising the anterior and posterior bands with interposing axillary pouch is an important static stabilizer of anterior translation and external rotation (ER) in the 90-degree abduction position. No literature is available to determine any ideal graft or isometric point for fixation of any graft to replace the functionality of IGHL such that the tensile stress acting on the graft is under the limits of the tensile properties of the graft used for reconstruction.

Methods: Using finite element method analysis (FEM) of the long head of the biceps tendon (LHBT) with modeling and simulation process, the ultimate tensile strength of the LHBT at the different clock positions of the humeral head attachment and angular positions of the humerus were determined through a combination of Taguchi Design of Experiments and simulation using ANSYS (Analysis system) software.

Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report.

Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may experience a complete response (CR), according to the mRECIST criteria. The treatment duration is until disease progression or unacceptable side effects occur.